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Most cases of cystic fibrosis (CF) are attributable to
the F508del allele of CFTR, which causes the protein
to be retained in the endoplasmic reticulum (ER) and
subsequently degraded. One strategy for CF therapy
is to identify corrector compounds that help traffic
F508del-CFTR to the cell surface. Pharmacological
chaperones, or correctors that bind specifically to
F508del-CFTR and restore function, would be the
most promising drug development candidates, but
few pharmacological chaperones exist for F508del-
CFTR. Using differential scanning fluorimetry (DSF),
we have surveyed corrector compounds and identi-
fied one, RDR1, which binds directly to the first
nucleotide binding domain (NBD1) of F508del-CFTR.
We show that RDR1 treatment partially rescues
F508del-CFTR function in both cells and in an
F508del-CF mouse model. Thus, RDR1 is a pharma-
cological chaperone of F508del-CFTR and repre-
sents a novel scaffold for drug development.
INTRODUCTION
Cystic fibrosis (CF) is the most common autosomal recessive
disease in Caucasians. It is caused by mutations in the gene
encoding the cystic fibrosis transmembrane conductance regu-
lator (CFTR) protein (Riordan et al., 1989). CFTR is a multidomain
cAMP-regulated chloride channel comprising two membrane-
spanning domains (MSD1 and 2), two nucleotide-binding
domains (NBD1 and 2), and a regulatory region that controls
the gating of the channel (Sheppard and Welsh, 1999). The
most common mutation is a deletion in NBD1 of the phenylala-
nine residue at position 508 (F508del), which causes misfolding
of the full-length protein. Consequently, F508del-CFTR is
retained in the ER and targeted for degradation rather than
trafficked to the plasma membrane (Welsh et al., 1993). The
trafficking of F508del-CFTR to the plasma membrane can be
corrected by incubating cells expressing the mutant protein at
reduced temperature (Denning et al., 1992). When properly
localized to the plasma membrane, F508del-CFTR is functional;Chemistry & Biology 18, 231however, it has defects in gating (Dalemans et al., 1991), and
a faster turnover at the cell surface than wild-type CFTR (Lukacs
et al., 1993).
The gating defect of corrected F508del-CFTR has led to the
discovery of compounds that can potentiate the channel’s
activity. Potentiators maximize CFTR channel activity when
CFTR is phosphorylated (Hwang et al., 1997). Potentiators are
thought to function via direct binding to the NBDs of CFTR to
modulate NBD dimerization, ATP binding and hydrolysis (Cai
et al., 2006; Vergani et al., 2005).
One approach to developing a potential treatment for CF is to
identify small molecule correctors of the F508del-CFTR
trafficking defect. Several high throughput screens for F508del-
CFTR trafficking correctors have been performed to date (Carlile
et al., 2007; Pedemonte et al., 2005; Van Goor et al., 2006); while
several compounds have been identified as putative F508del-
CFTR trafficking correctors, the mechanisms by which they
restore trafficking to the plasma membrane, which is funda-
mental to further development as candidate therapeutics,
remains elusive.
There are several possible mechanisms by which F508del-
CFTR trafficking may be corrected. The cell’s folding machinery,
ER recognition, or degradation mechanisms could be altered to
increase the proportion of F508del-CFTR that traffics to the cell
surface. As these mechanisms alter proteostatic balance in the
cell rather than F508del-CFTR itself, such correctors are termed
proteostasis regulators (Balch et al., 2008). Indeed, several puta-
tive proteostasis regulators have been identified to date: Aha1
(Wang et al., 2006a), 4-phenylbutyrate (Rubenstein et al.,
1997), glycerol (Brown et al., 1996), low temperature (Denning
et al., 1992), histone deacetylase (HDAC) inhibitors (Hutt et al.,
2010), phosphodiesterase 5 (PDE5) inhibitors (Dormer et al.,
2005; Robert et al., 2008), glafenine (Robert et al., 2010), and
miglustat (Norez et al., 2006). Since proteostasis regulators
indirectly affect F508del-CFTR trafficking, these correctors
may be nonspecific and may also correct the trafficking of other
ER-retained mutations. Another possibility is that correctors
could act specifically on F508del-CFTR as pharmacological
chaperones by binding directly to F508del-CFTR and promoting
the native fold such that the protein can evade ER quality control
and degradation. Pharmacological chaperones would be
expected to have fewer off-target effects and may be the most
conducive to the development of an effective treatment for CF.–242, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 231
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RDR1 Is an F508del-CFTR Pharmacological ChaperonePharmacological chaperones have been identified for other
ER-retained trafficking diseases including Fabry disease (Fan
et al., 1999), Gaucher disease (Sawkar et al., 2002), Tay-Sachs
and Sandhoff disease (Tropak et al., 2004), nephrogenic dia-
betes insipidus (Morello et al., 2000), and many others. These
compounds are generally active site inhibitors or substrate
mimics hence they bind directly to the mutant protein. To date
four correctors have been identified that might act as pharmaco-
logical chaperones of F508del-CFTR: VRT325, Corr4a and
VRT532 (Wang et al., 2006b, 2007b), and benzo[c]quinolizinium
(MPB) compounds (Becq et al., 1999; Dormer et al., 2001; Strat-
ford et al., 2003). CFTR constructs containing only the twoMSDs
of CFTR acquire more glycosylation upon VRT325 and Corr4a
treatment which suggests that these two correctors may bind
elsewhere than to the NBDs (Wang et al., 2007c). Homology
models of the CFTR protein constructed from the structure of
the bacterial transporter Sav1866 show that F508 is located at
an interface between the NBD1 and the fourth intracellular loop
(ICL4) in MSD2 (Mornon et al., 2008; Serohijos et al., 2008).
Based on this model, VRT325 and Corr4a may bind to the
MSD side of the interface. VRT325 has been shown recently to
decrease the affinity of partially purified F508del-CFTR for ATP
(Kim Chiaw et al., 2010), which also suggests direct binding to
F508del-CFTR. VRT532 may bind to a site at the interface
between the NBDs and the MSDs since it increases channel
open times but it does not alter the affinity of F508del-CFTR
for ATP (Wellhauser et al., 2009). MPB compounds have been
suggested to correct through their binding to the NBD1;
however, the effective concentrations required for correction
are very high (Becq et al., 1999; Dormer et al., 2001). Each of
these pharmacological chaperones has some limitations, either
in its effective concentration, toxicity profile, ability to correct
trafficking in multiple cell types and models, or the location of
the putative binding site lies outside the NBD1. Hence, there is
a need to identify potent NBD1-binding pharmacological
chaperones.
Differential scanning fluorimetry has been used successfully
to identify ligands that stabilize proteins for structural studies
(Niesen et al., 2007; Vedadi et al., 2006). We reasoned that this
technique could also be used to identify pharmacological chap-
erones of F508del-CFTR that act directly on the mutated
domain, NBD1. Here, we show that RDR1, a phenylhydrazone
compound initially identified in our cell-based trafficking
corrector assay, binds to and thermally stabilizes purified murine
F508del-NBD1 in vitro, and partially corrects trafficking of
F508del-CFTR in BHK cells and in human airway epithelial cells.
This trafficking correction results in a significant increase in
CFTR function in these two cell models, as well as in a mouse
model of cystic fibrosis. RDR1 and structurally related
compounds may thus provide new structural scaffolds for the
development of therapeutics to treat CF.
RESULTS
RDR1 Thermally Stabilizes F508del-NBD1
In order to identify F508del-CFTR pharmacological chaperones,
the hits that we obtained from our cell-based high-throughput
screen for CFTR correctors (Carlile et al., 2007) were tested
for stabilization of purified murine F508del-NBD1 in vitro.232 Chemistry & Biology 18, 231–242, February 25, 2011 ª2011 ElseUsing differential scanning fluorimetry (DSF), we first tested
a concentration series of ATP as a control (Figure 1A), given
that residues in the Walker A, B, and ABC signature motif in
NBD1 participate in two half-sites for ATP binding at the inter-
face of the NBD1-NBD2 heterodimer (Lewis et al., 2004; Moran
et al., 2005). We detected a dose-dependent increase in the
thermal stability of F508del-NBD1 at concentrations down to
50 mM ATP, the lowest concentration tested, which is similar
to the lowest Kd reported (88 ± 10 mM) for ATP binding to
NBD1 (Qu et al., 1997). We next screened 224 hit compounds
obtained from our corrector screen. Surprisingly, only one
compound (RDR1) was found to thermally stabilize F508del-
NBD1. RDR1 is a substituted phenylhydrazone from the May-
bridge library (Figure 1B). We tested a range of concentrations
of RDR1 and found a dose-dependent increase in F508del-
NBD1 thermal stability that was detectable at concentrations
of 5 mM or greater (Figure 1C). Interestingly, the thermal stabi-
lization of F508del-NBD1 with 20 mM RDR1 was greater than
that with 1 mM ATP (16C versus 7C, compare Figure 1C
and Figure 1A).
We obtained compounds that were structurally related to
RDR1 from Maybridge and ChemBridge and tested their ability
to stabilize F508del-NBD1 in DSF. RDR2 is a hydrazone similar
to RDR1, but it lacks the terminal phenyl ring (Figure 1B). A
compound obtained from the Chembridge library, RDR3, retains
this terminal phenyl ring, but it is a chlorosubstituted benzoic
acid (Figure 1B). Of these two related compounds, RDR3 also
showed thermal stabilization of F508del-NBD1 at concentra-
tions down to 5 mM (Figure 1D). However, RDR2 did not thermally
stabilize F508del-NBD1 even at concentrations up to 100 mM
(Figure 1E). We chose to focus on RDR1 for the remainder of
the study.
We next determined whether RDR1 was stabilizing
F508del-NBD1 by binding to the ATP binding half-sites or else-
where. We tested whether it competes with ATP for thermal
stabilization of F508del-NBD1. A range of concentrations of
ATP was added to F508del-NBD1 in the presence or absence
of 10 mM RDR1 and the thermal stability of F508del-NBD1 was
assessed (Figure 1F). In the presence of ATP, RDR1 stabilized
F508del-NBD1 by an additional 6C, which is consistent with
the thermal stabilization observed by RDR1 alone (Figures 1C
and 1F). This result suggests that RDR1 binds to a site other
than the ATP-binding half-sites in F508del-NBD1.
RDR1 Treatment Corrects Trafficking of Human
F508del-CFTR in BHK Cells and Human Airway
Epithelial Cells
To examine the effect of RDR1 on human F508del-CFTR in cells,
we tested its ability to correct trafficking in different cell types
and at different concentrations. BHK cells stably expressing
HA-tagged F508del-CFTR were treated with 10 mM RDR1 for
varying durations to determine the earliest time at which correc-
tion could be detected (Figure 2). As shown in Figure 2, an
increase in the amount of F508del-CFTR at the cell surface
was observed after 4 hr after treatment, with a maximal increase
(16%) detected after 18 hr of treatment. The onset of trafficking
correction observed with RDR1 treatment occurred at approxi-
mately the same time as that detected with VRT325; however,
themaximal RDR1 correction occurred earlier than that obtainedvier Ltd All rights reserved
Figure 1. RDR1 Stabilizes F508del-NBD1 Dose-Dependently
(A) Representative fractional unfolding curves of murine F508del-NBD1 in the presence of ATP.
(B) Chemical structures of RDR1 and related compounds. RDR1: 5-(4-nitrophenyl)-2-furaldehyde 2-phenylhydrazone; RDR2: 5-(4-nitrophenyl)-2-furaldehyde
2-methylhydrazone; RDR3: 5-(2-{[5-(2-bromo-4-nitrophenyl)-2-furyl] methylene} hydrazino)-2-chlorobenzoic acid.
(C) Representative fractional unfolding curves of F508del-NBD1 in the presence of RDR1.
(D) Representative fractional unfolding curves of F508del-NBD1 in the presence of RDR3.
(E) Representative fractional unfolding curves of F508del-NBD1 in the presence of RDR2.
(F) Effect of buffer, 1% DMSO, or 10 mM RDR1 on the stability of F508del-NBD1 in the presence of increasing concentrations of ATP. Error bars indicate SEM
(n = 3). Asterisks indicate statistically significant differences with a Student’s t test as compared with DMSO control (*p < 0.05, **p < 0.001).
See also Figure S1.
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RDR1 Is an F508del-CFTR Pharmacological Chaperonewith VRT325 treatment (18 versus 24 hr). Themaximal correction
with RDR1 corresponds to approximately 50% of the correction
obtained with 10 mM VRT325 at 24 hr.Chemistry & Biology 18, 231We next used immunoblotting in BHK cells stably overex-
pressing untagged F508del-CFTR to assess the maturation of
F508del-CFTR by its mobility in SDS-PAGE. F508del-CFTR–242, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 233
Figure 2. RDR1 Induces Trafficking of HA-Tagged F508del-CFTR to the Cell Surface in BHK Cells
A time course of F508del-CFTR trafficking in BHK cells treated with 10 mM RDR1 and 10 mM VRT325 treatments is shown. Error bars indicate SEM (n = 3).
A difference in the means as compared with the respective 0 hr time point was tested for statistical significance using a Student’s t test, *p < 0.05,
**p < 0.01, y p < 0.001.
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RDR1 Is an F508del-CFTR Pharmacological Chaperoneprotein that has trafficked to the Golgi acquires terminal glyco-
sylation (band C) and migrates more slowly in SDS-PAGE than
the immature ER-localized glycoform (band B), or the nonglyco-
sylated form (band A). We treated BHK cells with a range of
concentrations of RDR1 and quantified the blots by densitom-
etry (Figures 3A and 3B). Correction of F508del-CFTR trafficking
was detectable at concentrations of 10 mMRDR1 or greater (Fig-
ure 3A, lanes 7 and 8). As positive controls, we treated the cells
with the known corrector VRT325 (VRT325, lane 3) or incubated
them at 29C (lane 4). As shown in Figure 3B, a dose-dependent
increase in total CFTR protein, band B or C is detected with
increasing concentrations of RDR1, with 10 and 20 mM treat-
ments showing a statistically significant difference in band C
above the vehicle control. When the total amount of CFTR
protein or band B was compared, 20 mM RDR1 treatment
showed a statistically significant increase above the vehicle
control. When the ratio of C band to B band was calculated,
RDR1 concentrations of 10 and 20 mM showed an increase in
the C/B ratio; however, these differences were not statistically
significant (p = 0.066 and p = 0.096, respectively). When we
treated nonpolarized CFBE41o- airway epithelial cells that stably
overexpress F508del-CFTR with RDR1 for 24 hr, a similar dose-
dependent increase in F508del-CFTR trafficking was observed
(Figure 3C). In these cells, it appears that correction of
F508del-CFTR reached a maximum at 10 mM RDR1. These
results were quantified by densitometry (Figure 3D). Treatment
with 10 mM RDR1 resulted in a 1.2-fold increase in total CFTR
protein, but a 3.8-fold increase in band C as compared with
the vehicle control (Figure 3C, lane 1); however, this difference
was not statistically significant (p = 0.204).
To further elucidate the mechanism of RDR1 correction, we
tested for additivity with low temperature incubation, a treatment
that may correct trafficking by slowing down synthesis to allow234 Chemistry & Biology 18, 231–242, February 25, 2011 ª2011 Elsefolding of F508del-CFTR in the cell and also through proteostasis
regulation (Denning et al., 1992; Jurkuvenaite et al., 2010). If
RDR1 acts as a pharmacological chaperone, we would expect
it to be additive with low temperature treatment due to their
different mechanisms of action. BHK cells stably expressing
F508del-CFTR were treated with increasing concentrations of
RDR1 at 37C or at 29C. As expected, low temperature treat-
ment corrected trafficking of F508del-CFTR (Figure 3A, lane 4).
Treatment with RDR1 further increased the amount of correction
detected at 29C in a dose-dependent manner (Figure 3A,
compare lanes 9–11 to lanes 5–7). Quantification of these results
by densitometry shows that 10 mM RDR1 treatment doubled the
C/B ratio obtained with low temperature alone (Figure 3E). These
results confirm that RDR1 and low temperature treatment act
through complementary mechanisms.
RDR1 Treatment Corrects Human F508del-CFTR
Function
We next determined whether the correction we detect following
RDR1 treatment results in functional F508del-CFTR channels at
the cell surface. We first tested RDR1 in halide efflux assays
using BHK cells stably expressing F508del-CFTR (Figure 4A).
Treatment of BHK cells with 1 or 10 mM RDR1 resulted in
a 1.5- and 1.7-fold increase in functional F508del-CFTR, respec-
tively, as compared with the vehicle control (Figure 4B). As
a positive control, VRT325-treated cells resulted in a 3.3-fold
increase in functional channels. As expected, BHK cells stably
expressing wt-CFTR had 6.8-fold more functional channels
than F508del-CFTR cells treated with vehicle alone.
We next tested for functional correction of F508del-CFTR in
polarized CFBE41o- human airway epithelial cells overexpress-
ing F508del-CFTR (Figure 5). Short-circuit currents were
measured in Ussing chambers with an apical-to-basolateralvier Ltd All rights reserved
Figure 3. RDR1 Corrects Trafficking of F508del-CFTR in BHK Cells and Airway Epithelial Cells
(A) Immunoblot of BHK lysates stably overexpressing wild-type (WT) or F508del-CFTR (F508del) treated with RDR1 or 10 mM VRT325 at 37C or 29C,
as indicated. Lanes are numbered beneath the blot. Triangles indicate increasing concentrations. CFTR C band, B band, and tubulin are indicated with
arrows.
(B) Quantification of the band intensities for RDR1 treatments expressed as fold change of DMSO control. Error bars indicate SEM (n = 3). Asterisks indicate
statistically significant differences with a Student’s t test as compared with DMSO control (p < 0.05).
(C) Immunoblot of CFBE41o- lysates stably overexpressing CFTRwild-type (WT) or F508del-CFTR (F508del) treated at 37Cwith RDR1 or treated at 29C. Trian-
gles indicate decreasing concentrations. CFTR C band, B band, A band and tubulin are indicated with arrows.
(D) Quantification of the band intensities for RDR1 treatments is expressed as fold change of the DMSO control. Error bars indicate SEM (n = 3). Asterisks indi-
cate statistically significant differences with a paired Student’s t test as compared with DMSO control (p < 0.05).
(E) Quantification of the band intensities for increasing RDR1 concentrations on low temperature rescued F508del-CFTR expressed as fold change of 29C.
Error bars indicate SEM (n = 3). Asterisks indicate statistically significant differences with a paired Student’s t test as compared with the 29C control
(p < 0.05).
See also Figure S2.
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Figure 4. RDR1 Functionally Corrects F508del-CFTR in BHK Cells
(A) Iodide efflux assay measuring F508del-CFTR function at the plasma
membrane in BHK cells treated with DMSO, 1 mM RDR1, 10 mM RDR1, or
10 mM VRT325. Iodide efflux in untreated BHK cells expressing wt-CFTR
(wt) is also shown. An arrowhead and bar indicate addition and maintenance,
respectively, of 10 mM forskolin (Fsk) and 50 mMgenistein (Gst). Error bars indi-
cate SEM (n = 3).
(B) Change in iodide efflux upon stimulation with forskolin and genistein,
defined as the peak iodide efflux after stimulation subtracted from the baseline
response. Error bars indicate SEM (n = 3). A difference in the means as
compared with the DMSO control was tested for statistical significance using
paired t tests, *p < 0.05, ***p < 0.001.
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RDR1 Is an F508del-CFTR Pharmacological Chaperonechloride gradient after exposing monolayers to DMSO (Fig-
ure 5A), or 1 mM RDR1 for 24 hr (Figure 5B). Treatment with
10 mM VRT325 (Figure 5C) and low temperature (Figure 5D)
served as positive controls. A 1.5-fold increase in current was
detected following treatment with RDR1 as compared with the
vehicle-treated control (Figure 5E, p < 0.01, n = 4). Similarly,
VRT325 treatment induced an approximately 3-fold increase,
and low temperature treatment induced a 20-fold increase in
current above the vehicle-treated control (Figure 5E). These
data show that RDR1 can rescue F508del-CFTR function in
airway epithelial cells, albeit not as efficaciously as VRT325 or
low temperature.
Since we observed functional correction by RDR1 treatment
in multiple cell lines, we next tested for functional correction
in an F508del Cftr mouse model (French et al., 1996; van236 Chemistry & Biology 18, 231–242, February 25, 2011 ª2011 ElseDoorninck et al., 1995; Wilke et al., 2010). Mice were injected
with 1mg/kg/day of RDR1 or saline for 48 hr and salivary secre-
tion was monitored following beta-adrenergic stimulation. As
shown in Figure 6, we detected a significant increase in total sali-
vary secretion following treatment with RDR1 (67.54 mg.g-1 for
RDR1 versus 15.97 mg.g-1 for vehicle controls, p < 0.001). This
corresponds to approximately 7% of the salivary secretion
observed with wild-type littermates.
RDR1 Is a Weak Potentiator of Human F508del-CFTR
Function
Given that RDR1 binds to F508del-NBD1, we tested its ability to
potentiate F508del-CFTR function. We incubated polarized
CFBE41o- cells stably overexpressing F508del-CFTR at 29C
for 24 hr to rescue F508del-CFTR, measured short circuit
currents following addition of 10 mM forskolin, and then added
acutely DMSO, RDR1 or genistein (Figure 7). Representative
traces are shown in Figure 7A. Treatment with 20 mM RDR1
resulted in a small increase in current (Figures 7A and 7B);
however, 50 mM RDR1 treatment gave a statistically significant
increase equivalent to approximately 9% of that detected with
50 mM genistein (Figures 7A–7C, p < 0.01, n = 3). The current
declined to baseline following addition of CFTRinh-172, which
indicates that it is generated by F508del-CFTR.
DISCUSSION
We set out to find pharmacological chaperones for
F508del-CFTR among the trafficking correctors identified in
our cell-based screen (Carlile et al., 2007). Of over 220 correctors
screened, only one, RDR1, thermally stabilized purified F508del-
NBD1. The small number of pharmacological chaperones
among our correctors could be attributed to the chemical
libraries that were screened, the use of murine F508del-NBD1
as a screening tool, or alternatively, we may have missed those
that bind elsewhere than the NBD1. We have shown that RDR1
thermally stabilizes isolated F508del-NBD1 in a manner similar
to ATP, suggesting that it acts as a pharmacological chaperone
of F508del-CFTR. RDR1 is the highest affinity NBD1-binding
pharmacological chaperone found so far. RDR1 does not bind
to the ATP binding site since ATP and RDR1 additively stabilize
F508del-NBD1 against thermal denaturation. The structurally
related compound RDR3 also stabilizes F508del-NBD1;
however, RDR2, which lacks a terminal phenyl ring present in
RDR1, does not thermally stabilize F508del-NBD1. These results
suggest that this phenyl ring may be an important moiety for
mediating the interaction with F508del-NBD1. We have shown
that RDR1 treatment corrects F508del-CFTR trafficking in both
BHK and CFBE41o- cells and in a mouse model of CF. Acute
addition of RDR1 to polarized CFBE41o- cells shows that it is
a weak potentiator of F508del-CFTR function, which is consis-
tent with a mechanism of action that involves binding to
F508del-NBD1 (Cai et al., 2006).
Several potentiators that are postulated to bind directly to the
NBDs of CFTR have been identified to date, including genistein
(French et al., 1997), MPB compounds (Becq et al., 1999;
Galietta et al., 2001), phloxine B (Bachmann et al., 2000; Cai
and Sheppard, 2002), capsaicin (Ai et al., 2004), and VRT532
(Van Goor et al., 2006; Wellhauser et al., 2009). However, nonevier Ltd All rights reserved
Figure 5. RDR1 Functionally Corrects
F508del-CFTR in Airway Epithelial Cells
(A–D) CFBE41o- cells stably overexpressing
F508del-CFTR were treated with (A) vehicle
control (DMSO), (B) 1 mM RDR1, (C) 10 mM
VRT325, or (D) vehicle control at 29C for 24 hr
and current was measured in an Ussing chamber.
In (A)–(D), arrowheads and bars indicate addition
and maintenance, respectively, of 10 mM forskolin
(Fsk), 50 mM genistein (Gst), and 10 mM
CFTRinh-172 (inh172).
(E) Bar graph showing the change in Isc (DIsc) after
adding forskolin (white) or forskolin + genistein
(black), defined as the difference between the
peak of the sustained phase of the current
response after forskolin or genistein, respectively,
and the baseline before stimulation. Mean
currents for each treatment are shown. Error
bars indicate SEM (n = 4). Means were tested for
statistical significance using a Student’s t test;
**p < 0.01, ***p < 0.001.
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RDR1 Is an F508del-CFTR Pharmacological Chaperoneof the binding sites for these potentiators have been precisely
located on CFTR. MPB compounds are postulated to interact
with NBD1 via glycine 622, since mutation of this residue abol-
ishes correction by these compounds (Norez et al., 2008). Gen-
istein and many other potentiators are hypothesized to bind to
the interface of the NBD1-NBD2 heterodimer with a surface
involving the Walker A, B, and ABC signature of NBD1 and
with the ABC signature motif of NBD2 (Moran et al., 2005). This
hypothesis is consistent with the finding that the G551D and
the V1293G mutations alter the affinity of these molecules for
CFTR (Moran et al., 2005; Zegarra-Moran et al., 2007). Capsaicin
likely binds to the same site since it competes with genistein (Ai
et al., 2004). We tested genistein and capsaicin in our DSF
screen and we were unable to detect thermal stabilization of
F508del-NBD1 (data not shown). This result may indicate that
both NBDs are required to bind to these potentiators. We also
tested whether we could detect thermal stabilization with
VRT532, a dual corrector/potentiator (Van Goor et al., 2006;
Wang et al., 2006b, 2007b). Although we did see some stabiliza-Chemistry & Biology 18, 231–242, February 25, 2011tion of F508del-NBD1 with VRT532, it
was only observed at very high (100 mM)
concentrations (see Figure S1 available
online). Interestingly, VRT532 is hypothe-
sized to bind to a site between the NBD
and MSD of F508del-CFTR rather than
at the heterodimer interface (Wellhauser
et al., 2009). This difference may explain
why VRT532 can thermally stabilize
F508del-NBD1 while genistein and
capsaicin cannot. These findings suggest
that RDR1 might bind to a site other than
at the interface between the two NBDs.
Treatment with RDR1 caused a signifi-
cant increase in F508del-CFTR function
for all cell types presented here. In BHK
cells, 10 mM RDR1 treatment resulted
in 29% of the halide efflux observedwith 10 mM VRT325 (Figure 4); in polarized CFBE41o- cells,
1 mMRDR1 treatment resulted in 25%and 2.5% of the functional
correction achieved with 10 mM VRT325 and low temperature
treatment, respectively (Figure 5). In the CF mouse, 1 mg/kg/
day treatment of RDR1 resulted in approximately 7% of the
salivary gland secretion observed in wild-type littermates (Fig-
ure 6). Conversely, treatment of BHK cells with RDR2, which
does not thermally stabilize F508del-NBD1 in DSF, did not
inducematuration of F508del-CFTR (Figure S2). Acute treatment
of polarized CFBE41o- cells with RDR1 shows that it is a weak
potentiator (Figure 7). This contrasts with VRT325, which has
recently been shown to partially inhibit CFTR (Kim Chiaw et al.,
2010). Taken together, these results indicate that thermal stabi-
lization of F508del-NBD1 by RDR1 is correlated with an increase
in F508del-CFTR maturation and function, which is consistent
with the action of a pharmacological chaperone.
We have shown that RDR1 treatment is additive with low
temperature correction, which is consistent with a mechanism
of action that differs from proteostasis regulation. Interestingly,ª2011 Elsevier Ltd All rights reserved 237
Figure 6. RDR1 Functionally Corrects F508del-CFTR in a Mouse
Model of Cystic Fibrosis
Salivary secretion in wild-type mice (WT) or F508del-CFTR (F508del) mice
treated with vehicle alone (vehicle) or 1mg/kg/day of RDR1 (RDR1) for
2 days was monitored for 30 min following stimulation. Results shown are
for WT: n = 6, vehicle: n = 5, RDR1: n = 7. Means were tested for statistical
significance using a Student’s t test; **p < 0.01, ***p < 0.001 . Error bars indi-
cate SEM.
See also Figure S3.
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RDR1 Is an F508del-CFTR Pharmacological ChaperoneCorr4a and VRT325 treatment is also additive with low tempera-
ture correction (Pedemonte et al., 2010). Additionally, reports
have suggested that Corr4a and VRT325 may bind to different
sites on F508del-CFTR, as simultaneous treatment with these
correctors had an additive effect on F508del-CFTR maturation
(Pedemonte et al., 2010; Wang et al., 2007a). Given that
constructs containing only the two MSDs of CFTR can acquire
glycosylation upon VRT325 and Corr4a treatment (Wang et al.,
2007c), these two correctors likely do not bind to the NBDs.
Hence RDR1 is the most potent NBD1-binding pharmacological
chaperone identified to date. Additionally, RDR1 treatment of
human embryonic kidney cells for 24 hr did not inhibit the
proliferation of these cells suggesting that it is not toxic to human
cells at the concentrations that generate functional correction
(Figure S3). This result contrasts the reported cytotoxicity of
VRT325 (Robert et al., 2010). As the level of correction detected
with a single corrector is quite small, a combinatorial approach
(i.e., either two correctors, or a corrector and potentiator) will
likely be necessary to generate a significant increase in CFTR
function to ameliorate the symptoms of CF (Jurkuvenaite et al.,
2010). RDR1 represents a promising lead for further develop-
ment as a potential addition to a new generation of CF
treatments.SIGNIFICANCE
Although themost commonmutation causing cystic fibrosis
(CF), F508del-CFTR, has been known for over 20 years (Rior-
dan et al., 1989), we still do not have a cure for this disease.
F508del-CFTR is recognized by the cellular quality control238 Chemistry & Biology 18, 231–242, February 25, 2011 ª2011 Elsemachinery and degraded rather than being trafficked to
the cell surface where it functions as a chloride channel.
One approach to developing a cure for CF is to identify small
molecules that correct the basic trafficking defect. Themost
specific small molecule trafficking correctors would be
pharmacological chaperones that bind directly to the
F508del-CFTR protein. Few pharmacological chaperones
exist for F508del-CFTR that are not limited either in effective
concentration, toxicity profile, ability to correct trafficking in
multiple cell types andmodels, or the location of the putative
binding site lies outside the NBD1. Our data suggest that
RDR1 is the most potent NBD1-binding pharmacological
chaperone identified to date that corrects trafficking in
multiple cell models and that does not appear to be toxic
to human cells and mice. However, estimates of the correc-
tion level required to ameliorate the symptoms of CF range
between 10% and 30% of wild-type CFTR function (McKone
et al., 2003; Zhang et al., 2009), a level that cannot be
achieved by a single pharmacological chaperone. Hence,
a combination of correctors with different mechanisms of
action will likely be necessary to cure this disease (Jurkuve-
naite et al., 2010; Van Goor et al., 2006).
EXPERIMENTAL PROCEDURES
Cloning
Murine NBD1 (residues 389–673) and F508del-NBD1 constructs were gener-
ated by PCR using pET15-mCFTR as a template and appropriate primers
(50-TCCGGAACCACAGGCATAATCATGG-30 and 50-GGATCCTTAATCGTCTA
CTGAGAAC-30) and subcloned into pETSUMO (Invitrogen). The SUMO-
Histidine tagged proteins were expressed in Escherichia coli and purified
according to published procedures with slight modifications (Lewis et al.,
2004). In brief, proteins were purified on Nickel Sepharose Fast Flow resin
(GE Biosciences) and eluted with an imidazole step gradient (20 mM Tris,
250 mM NaCl, 400 mM imidazole, 12.5% glycerol [pH 7.6]). ATP was added
to eluted fractions to a final concentration of 2 mM. Fractions containing the
SUMO-NBD1 were pooled and cleaved with a partially purified GST-ULP1
C-terminal conserved fragment kindly provided by Dr. Gregor Jansen (McGill
University). The cleavage reaction was then separated on an S200 gel filtration
column (GE Biosciences) equilibrated with the following buffer: 50 mM Tris,
150 mM NaCl, 5 mM MgCl2, 2 mM ATP, 2 mM 2-mercaptoethanol, 12.5%
glycerol (pH 7.6). Fractions containing the cleaved F508del-NBD1were pooled
and concentrated with a 10,000-molecular weight cutoff spin filter column
(Amicon).
Differential Scanning Fluorimetry
Differential scanning fluorimetry was performed using an Mx3005P instru-
ment (Stratagene) as described (Vedadi et al., 2006). In brief, purified NBD1
or F508del-NBD1 was diluted in DSF buffer (100 mM HEPES, 150 mM
NaCl [pH 7.4]) containing 5X Sypro Orange dye (Sigma-Aldrich) to a final
concentration of 4 mM and aliquoted. DMSO or corrector compounds were
added to the protein solution such that the final DMSO concentration was
1%. The solution was mixed gently and transferred to a 96-well plate (Strata-
gene) in duplicate. The plate was sealed with optical tape (Bio-Rad) and
centrifuged at low speed to remove bubbles. The samples were then imme-
diately run in the Mx3005P instrument using the excitation filter for carboxy-
fluorescein (FAM, 492 nm) and emission filter for Cy3 (568 nm) or Texas red
(610 nm). Results were exported to Excel (Microsoft) and the apparent
melting temperatures were obtained by fitting the curves using the Boltzmann
equation and XLFit 4 software (IDBS). Fractional unfolding curves were
generated with the following equation: (FT – Fmin) / (Fmax – Fmin), where FT indi-
cates fluorescence at temperature T, Fmin indicates the minimum fluores-
cence and Fmax indicates the maximum fluorescence. Experiments were per-
formed at least three times.vier Ltd All rights reserved
Figure 7. RDR1 Potentiates F508del-CFTR
Function in Polarized Airway Epithelial Cells
(A) Representative traces from short circuit
currents measured in Ussing chamber on polar-
ized CFBE41o- cells overexpressing F508del-
CFTR incubated at 29C for 24 hr, stimulated
with 10 mM forskolin, and then treated acutely
with DMSO, 20 mM RDR1, 50 mM RDR1, or
50 mM genistein, followed by the addition of
10 mM CFTRinh-172 (inh172), as indicated by
arrowheads and bars.
(B) Bar graph showing the change in Isc (DIsc) after
adding DMSO, RDR1, or genistein after the forsko-
lin-stimulated Isc, defined as the difference
between the sustained phase of the current
response after DMSO, RDR1, or genistein and the
sustained phase of the current response after for-
skolin. Mean currents for each treatment (n = 3).
Error bars indicate SEM, ***p < 0.001, ## p < 0.01.
(C) Currents generated by RDR1 treatment nor-
malized to genistein treatment.
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BHK cells stably transfected with human F508del-CFTR were cultured under
standard conditions in DMEM-F12 media supplemented with 5% FBS and
450 mM methotrexate. CFBE41o- cells stably transfected with F508del-CFTR
were cultured under standard conditions in EMEM supplemented with 10%
FBS and 1% L-Glutamax. Compounds for treatment were diluted from DMSO
stocks into fresh media such that the final concentration of DMSO was 0.1%.
Western Blotting
Western blotting was performed according to published procedures (Carlile
et al., 2007), with a mouse monoclonal antibody raised against the R domain
of CFTR (Myriam Mirza, Veli-Pekka Ma¨a¨tta¨nen and D.Y.T., unpublished
data). The relative levels of each CFTR glycoformwere estimated by densitom-
etry using Photoshop (Adobe Inc.). The values reported are expressed as
means ± SEM (n = 3). Data sets were compared by a Student’s t test using
SigmaPlot (Systat Software, Inc.).
Iodide Efflux Assays
Iodide efflux assays with stably transfected BHK cells expressing
histidine-tagged wt-CFTR or F508del-CFTR were performed according to
published procedures (Robert et al., 2010). CFTR-mediated iodide efflux
was stimulated with 10 mM forskolin and 50 mM genistein at room
temperature. Values reported are means ± SEM (n = 3). Data sets were
compared with DMSO by paired t test using SigmaPlot (Systat Software, Inc.).Chemistry & Biology 18, 231–242, February 25, 2011Ussing Chamber
We used the CFBE41o- airway epithelial cell line
subsequently transduced with TranzVector lenti-
vectors containing F508del-CFTR, which was
generously provided by Dr. J.P. Clancy (University
of Alabama at Birmingham, Birmingham, AL). Cells
were seeded at a density of 2.5 3 105 cells/cm2
onto 12 mm fibronectin-coated Snapwell inserts
(Corning Incorporated). The apical medium was
removed after 24 hr to establish an air-liquid inter-
face, and then the cells were cultured for another
6–7 days. Cells were treated on both sides with
optiMEM containing 1 mM RDR1, 10 mM VRT325,
or DMSO (1/1000) at 37C, or incubated at 29C
for 24 hr, before being mounted in EasyMount
chambers and voltage clamped using a VCCMC8
multichannel current-voltage clamp (Physiologic
Instruments). The apical membrane conductance
was functionally isolated by permeabilizing thebasolateral membrane with 200 mg/ml nystatin and imposing an apical-
to-basolateral Cl- gradient. The basolateral bathing solution contained
1.2 mM NaCl, 115 mM Na-gluconate, 25 mM NaHCO3, 1.2 mM MgCl2,
4 mM CaCl2, 2.4 mM KH2PO4, 1.24 mM K2HPO4 and 10 mM glucose
(pH 7.4). The CaCl2 concentration was increased to 4 mM to compensate
for the chelation of calcium by gluconate. The apical bathing solution con-
tained 115 mM NaCl, 25 mM NaHCO3, 1.2 mM MgCl2, 1.2 mM CaCl2,
2.4 mM KH2PO4, 1.24 mM K2HPO4, and 10 mM mannitol (pH 7.4). The apical
solution contained mannitol instead of glucose to eliminate currents mediated
by Na+-glucose cotransport. Successful permeabilization of the basolateral
membrane was obvious from the reversal of Isc under these conditions. Solu-
tions were continuously gassed and stirred with 95% O2 and 5% CO2 and
maintained at 37C. Ag/AgCl reference electrodes were used to measure
transepithelial voltage and pass current. Pulses (1 mV amplitude, 1 s duration)
were delivered every 90 s tomonitor resistance. The voltage clamps were con-
nected to a PowerLab/8SP interface for data collection. For correction exper-
iments, 10 mM forskolin and 50 mM genistein were added sequentially to the
apical side followed by an addition of 10 mM of CFTRinh-172 to the apical
side to demonstrate that measured currents were due to CFTR activity.
UTP (100 mM) was added at the end of the experiment to the apical side to
demonstrate the viability of the cells (data not shown). Transepithelial
resistances of the epithelia were 300–400 Ohm/cm2. For potentiation
experiments, cells were incubated at 29C for 24 hr, 10 mM forskolin was
added to the apical side followed by acute addition of DMSO, 20 mM RDR1,ª2011 Elsevier Ltd All rights reserved 239
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RDR1 Is an F508del-CFTR Pharmacological Chaperone50 mM RDR1, or 50 mM genistein. The addition of 10 mM of CFTRinh-172 to the
apical side was performed to demonstrate that measured currents were due to
CFTR activity.Salivary Secretion Experiments
Themethods usedwere similar to those described by Best andQuinton (2005).
The procedures followed all CIHR regulations, and the protocol was approved
by the Animal Care Committee ofMcGill University. In brief, 10- to 12-week-old
homozygous F508del-CFTR mice (backcrossed on the FVB genetic back-
ground for more than 12 generations, Cftrtm1 Eur) (van Doorninck et al., 1995)
and littermate wild-type controls weighing between 23 and 33 g were injected
intraperitoneally with saline containing RDR1 (1 mg/kg/day) or vehicle alone
(0.1% DMSO) for 2 days and monitored closely for possible adverse effects.
The mice were anaesthetized with a combination of ketamine and diazepam
on the day of the experiment and maintained on a flat surface in supine orien-
tation with adhesive tape. The mouth was held open by cephalic retraction of
the dorsal front teeth with a rubber band. An indirect heat lamp warmed the
animals during the saliva collection period. Mice were pretreated with a subcu-
taneous injection of 50 ml (1 mM) atropine into the left cheek as a cholinergic
antagonist. A 2 3 25 mm piece of Whatman filter paper was placed inside
the previously injected cheek for approximately 4 min to absorb any saliva.
Solution (100 ml) containing 100 mM isoprenaline and 1 mM atropine was
then injected into the left cheek at the same site to induce secretion at time
zero and the filter paper was replaced every 3 min for 30 min. Each piece of
filter paper was immediately placed and sealed in a pre-weighed vial and
the time of removal was recorded. The total salivary secretion was normalized
to the mass of the mouse in grams. Results are expressed as the mean ± SEM
of n mice.SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/j.
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